Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva-Kowa To Commence Marketing Generics In Japan In January

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Teva-Kowa Pharma, a ¥360 million 50-50 joint venture of Teva - the world's largest generics manufacturer - and Japan's diversified manufacturer group Kowa, Dec. 16 said it would commence marketing generic drugs in Japan beginning in January, a few months ahead of schedule

You may also be interested in...



Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy

MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind

Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy

MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind

Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition

Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff

Related Content

UsernamePublicRestriction

Register

SC070620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel